Srinivasan Venkatesh 4
4 · SUTRO BIOPHARMA, INC. · Filed Mar 4, 2025
Insider Transaction Report
Form 4
Srinivasan Venkatesh
CHIEF TECH OP OFFICER
Transactions
- Exercise/Conversion
Common Stock
2025-03-01+6,375→ 43,105 total - Tax Payment
Common Stock
2025-03-01$1.59/sh−4,672$7,428→ 38,433 total - Exercise/Conversion
Common Stock
2025-03-01+5,000→ 36,730 total - Exercise/Conversion
Restricted Stock Unit (RSU)
2025-03-01−5,000→ 10,000 totalExp: 2027-03-01→ Common Stock (5,000 underlying) - Exercise/Conversion
Restricted Stock Unit (RSU)
2025-03-01−6,375→ 19,125 totalExp: 2028-03-01→ Common Stock (6,375 underlying)
Footnotes (4)
- [F1]Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
- [F2]Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
- [F3]The RSUs vest as to 1/4th of the total shares annually beginning on March 1, 2024, subject to continued service through each vesting date.
- [F4]The RSUs vest as to 1/4th of the total award annually beginning on March 1, 2025, subject to continued service through each vesting date.